Seventy years after his death, a Calgary soldier who was wounded in the First World War was honoured Sunday with a military ...

Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...

The current recommended urine protein to creatinine ratio is arbitrary, and a lower bar would capture more lupus nephritis ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

The FDA has approved Gazyva (obinutuzumab) for treating adult patients with active lupus nephritis who are already on ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring ...